Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug-Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole.
Journal
European journal of drug metabolism and pharmacokinetics
ISSN: 2107-0180
Titre abrégé: Eur J Drug Metab Pharmacokinet
Pays: France
ID NLM: 7608491
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
pubmed:
17
10
2020
medline:
24
9
2021
entrez:
16
10
2020
Statut:
ppublish
Résumé
Proton pump inhibitors (PPIs) can affect the intragastric release of other drugs from their dosage forms by elevating the gastric pH. They may also influence drug absorption and metabolism by interacting with P-glycoprotein or with the cytochrome P450 (CYP) enzyme system. Nifedipine is a Biopharmaceutics Classification System (BCS) class II drug with low solubility across physiologic pH and high permeability. Previous studies have demonstrated that drug-drug interaction (DDI) existed between omeprazole and nifedipine with significantly increased systemic exposure of nifedipine in subjects after pre-treatment for 7 days with omeprazole compared to the subjects without omeprazole treatment. It was shown that omeprazole not only induced an increase in intragastric pH, but also inhibited the CYP3A4 activity, while CYP3A4-mediated oxidation is the main metabolic pathway of nifedipine. The purpose of this study is to apply a physiologically based pharmacokinetic (PBPK) modeling approach to investigate the DDI mechanism for an immediate release formulation of nifedipine with omeprazole. A previously published model for omeprazole was modified to integrate metabolites and to update CYP inhibition based on the most updated published in vitro data. We simulated the nifedipine pharmacokinetics in healthy subjects with or without the multiple-dose pretreatment of omeprazole (20 mg) following oral administrations of immediate-release (IR) (10 mg) nifedipine. Nifedipine solubility at different pHs was used to simulate the nifedipine pharmacokinetics for both clinical arms. Multiple sensitivity analyses were performed to understand the impact of gastric pH and the CYP3A4-mediated gut and liver first pass metabolism on the overall nifedipine pharmacokinetics. The developed PBPK model properly described the pharmacokinetics of nifedipine and predicted the inhibitory effect of multiple-dose omeprazole on CYP3A4 activity. With the incorporation of the physiologic effect of omeprazole on both gastric pH and CYP3A4 to the PBPK model, the verified PBPK model allows evaluating the impact of the increase in gastric pH and/or CYP3A4 inhibition. The simulated results show that the nifedipine metabolic inhibition by omeprazole may play an important role in the DDI between nifedipine and omeprazole for IR nifedipine formulation. The developed full PBPK model with the capability to simulate DDI by considering gastric pH change and metabolic inhibition provides a mechanistic understanding of the observed DDI of nifedipine with a PPI, omeprazole.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Proton pump inhibitors (PPIs) can affect the intragastric release of other drugs from their dosage forms by elevating the gastric pH. They may also influence drug absorption and metabolism by interacting with P-glycoprotein or with the cytochrome P450 (CYP) enzyme system. Nifedipine is a Biopharmaceutics Classification System (BCS) class II drug with low solubility across physiologic pH and high permeability. Previous studies have demonstrated that drug-drug interaction (DDI) existed between omeprazole and nifedipine with significantly increased systemic exposure of nifedipine in subjects after pre-treatment for 7 days with omeprazole compared to the subjects without omeprazole treatment. It was shown that omeprazole not only induced an increase in intragastric pH, but also inhibited the CYP3A4 activity, while CYP3A4-mediated oxidation is the main metabolic pathway of nifedipine. The purpose of this study is to apply a physiologically based pharmacokinetic (PBPK) modeling approach to investigate the DDI mechanism for an immediate release formulation of nifedipine with omeprazole.
METHODS
METHODS
A previously published model for omeprazole was modified to integrate metabolites and to update CYP inhibition based on the most updated published in vitro data. We simulated the nifedipine pharmacokinetics in healthy subjects with or without the multiple-dose pretreatment of omeprazole (20 mg) following oral administrations of immediate-release (IR) (10 mg) nifedipine. Nifedipine solubility at different pHs was used to simulate the nifedipine pharmacokinetics for both clinical arms. Multiple sensitivity analyses were performed to understand the impact of gastric pH and the CYP3A4-mediated gut and liver first pass metabolism on the overall nifedipine pharmacokinetics.
RESULTS
RESULTS
The developed PBPK model properly described the pharmacokinetics of nifedipine and predicted the inhibitory effect of multiple-dose omeprazole on CYP3A4 activity. With the incorporation of the physiologic effect of omeprazole on both gastric pH and CYP3A4 to the PBPK model, the verified PBPK model allows evaluating the impact of the increase in gastric pH and/or CYP3A4 inhibition. The simulated results show that the nifedipine metabolic inhibition by omeprazole may play an important role in the DDI between nifedipine and omeprazole for IR nifedipine formulation.
CONCLUSION
CONCLUSIONS
The developed full PBPK model with the capability to simulate DDI by considering gastric pH change and metabolic inhibition provides a mechanistic understanding of the observed DDI of nifedipine with a PPI, omeprazole.
Identifiants
pubmed: 33064292
doi: 10.1007/s13318-020-00649-x
pii: 10.1007/s13318-020-00649-x
doi:
Substances chimiques
Calcium Channel Blockers
0
Cytochrome P-450 CYP3A Inhibitors
0
Proton Pump Inhibitors
0
Nifedipine
I9ZF7L6G2L
Omeprazole
KG60484QX9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
41-51Références
Grimm SW, Einolf HJ, Hall SD, He K, Lim H-K, Ling K-HJ, et al. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos Biol Fate Chem. 2009;37:1355–70.
doi: 10.1124/dmd.109.026716
Gajendran J, Krämer J, Shah VP, Langguth P, Polli J, Mehta M, et al. Biowaiver monographs for immediate-release solid oral dosage forms: nifedipine. J Pharm Sci. 2015;104:3289–98.
doi: 10.1002/jps.24560
US. FDA. PROCARDIA® (nifedipine) CAPSULES For Oral Use [Internet]. 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018482s051lbl.pdf . Accessed 20 Aug 2020.
Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem. 1986;261:5051–60.
doi: 10.1016/S0021-9258(19)89213-X
Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos Biol Fate Chem. 2011;39:2020–33.
doi: 10.1124/dmd.111.041293
Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos Biol Fate Chem. 1997;25:853–62.
pubmed: 9224780
Li X-Q, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos Biol Fate Chem. 2004;32:821–7.
doi: 10.1124/dmd.32.8.821
Shirasaka Y, Sager JE, Lutz JD, Davis C, Isoherranen N. Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions. Drug Metab Dispos Biol Fate Chem. 2013;41:1414–24.
doi: 10.1124/dmd.113.051722
Soons PA, van den Berg G, Danhof M, van Brummelen P, Jansen JB, Lamers CB, et al. Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol. 1992;42:319–24.
doi: 10.1007/BF00266355
US FDA. Evaluation of formulation dependence of drug-drug interaction with proton pump inhibitors (PPIs) for oral extended-release drug products; Contract #: HHSF223201610004I [Internet]. https://www.fda.gov/industry/generic-drug-user-fee-amendments/fy2016-regulatory-science-report-modified-release-drug-products-therapeutic-equivalence-between . Accessed 20 Aug 2020.
Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49:509–33.
doi: 10.2165/11531320-000000000-00000
Wedemeyer R-S, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37:201–11.
doi: 10.1007/s40264-014-0144-0
Wu F, Gaohua L, Zhao P, Jamei M, Huang S-M, Bashaw ED, et al. Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: application to predict drug/genetic interactions. Pharm Res. 2014;31:1919–29.
doi: 10.1007/s11095-013-1293-z
Patel N, Polak S, Jamei M, Rostami-Hodjegan A, Turner DB. Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2014;57:240–9.
Liu F, Shokrollahi H. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer. Int J Pharm. 2015;485:152–9.
doi: 10.1016/j.ijpharm.2015.03.008
Hassan-Alin M, Andersson T, Niazi M, Röhss K. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. Eur J Clin Pharmacol. 2005;60:779–84.
doi: 10.1007/s00228-004-0841-1
Andersson T, Weidolf L. Stereoselective disposition of proton pump inhibitors. Clin Drug Investig. 2008;28:263–79.
doi: 10.2165/00044011-200828050-00001
Vieira MLT, Zhao P, Berglund EG, Reynolds KS, Zhang L, Lesko LJ, et al. Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor. Clin Pharmacol Ther. 2012;91:700–8.
doi: 10.1038/clpt.2011.305
Prichard PJ, Yeomans ND, Mihaly GW, Jones DB, Buckle PJ, Smallwood RA, et al. Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology. 1985;88:64–9.
doi: 10.1016/S0016-5085(85)80133-5
Ali SL. Nifedpine. In: Florey K, Al-Badr AA, Forcier GA, Brittain HG, Grady LT, editors. Anal Profiles Drug Subst. New York: Academic Press; 1990. pp. 221–88. https://www.sciencedirect.com/science/article/pii/S0099542808606747 . Accessed 28 May 2019.
Hsueh C-H, Hsu V, Pan Y, Zhao P. Predictive performance of physiologically-based pharmacokinetic models in predicting drug-drug interactions involving enzyme modulation. Clin Pharmacokinet. 2018;57:1337–466.
doi: 10.1007/s40262-018-0635-8
Min JS, Bae SK. Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling. Arch Pharm Res. 2017;40:1356–79.
doi: 10.1007/s12272-017-0976-0
Zhuang X, Lu C. PBPK modeling and simulation in drug research and development. Acta Pharm Sin B. 2016;6:430–40.
doi: 10.1016/j.apsb.2016.04.004
US. FDA. In vitro metabolism- and transporter-mediated drug-drug interaction studies guidance for industry [Internet]. 2017. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/vitro-metabolism-and-transporter-mediated-drug-drug-interaction-studies-guidance-industry . Accessed 20 Aug 2020.
US. FDA. Clinical drug interaction studies—study design, data analysis, and clinical implications guidance for industry [Internet]. 2017. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-study-design-data-analysis-and-clinical-implications-guidance . Accessed 20 Aug 2020.
Grimstein M, Yang Y, Zhang X, Grillo J, Huang S-M, Zineh I, et al. Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. food and drug administration’s office of clinical pharmacology. J Pharm Sci. 2019;108:21–5.
doi: 10.1016/j.xphs.2018.10.033
Zhao P. “Towards consistent regulatory assessment of physiologically-based pharmacokinetic modeling to support dosing recommendations.” FDA pharmaceutical science and clinical pharmacology advisory committee meeting, 15 March 2017, Washington, DC. Presentation. 2017. https://www.fda.gov/media/104616/download . Accessed 20 Aug 2020.
Lobo J, Jack DB, Kendall MJ. The intra- and inter-subject variability of nifedipine pharmacokinetics in young volunteers. Eur J Clin Pharmacol. 1986;30:57–60.
doi: 10.1007/BF00614196
Overton ET, Tschampa JM, Klebert M, Royal M, Rodriguez M, Spitz T, et al. The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy. J Clin Pharmacol. 2010;50:1050–5.
doi: 10.1177/0091270009357431
Suri A, Bramer SL. Effect of omeprazole on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37(Suppl 2):53–9.
doi: 10.2165/00003088-199937002-00006
Dean L. Omeprazole therapy and CYP2C19 genotype. In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A, editors. Med Genet Summ [Internet]. Bethesda (MD): National center for biotechnology information (US); 2012. https://www.ncbi.nlm.nih.gov/books/NBK100895/ . Accessed 28 May 2019
Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001;40:411–26.
doi: 10.2165/00003088-200140060-00003
US. FDA. Clinical pharmacology review, application number: 21-153/21-154 [Internet]. 2000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21154_nexium_biopharmr_p1.pdf . Accessed 20 Aug 2020.
Uno T, Niioka T, Hayakari M, Yasui-Furukori N, Sugawara K, Tateishi T. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. Eur J Clin Pharmacol. 2007;63:143–9.
doi: 10.1007/s00228-006-0251-7
Kita T, Sakaeda T, Aoyama N, Sakai T, Kawahara Y, Kasuga M, et al. Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. Biol Pharm Bull. 2002;25:923–7.
doi: 10.1248/bpb.25.923